Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to potent and specific silencing of BRD4 in NK cells without affecting cell viability.
2. It boosts NK cell numbers by enhancing proliferation during ex vivo expansion.
3. PH-894 decreases expression of CD94, an inhibitory receptor, potentially improving cytotoxic potential.
4. It may improve NK cell efficacy in adoptive cell therapies.
5. PH-894 serves as a foundation for future NK cell-based immunotherapies.
The presentation by Melissa Maxwell is scheduled for October 16, 2024, from 8 a.m. to 6:45 p.m. ET in the FDR Ballroom.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) presenterà dati sul suo composto INTASYL PH-894 alla conferenza ASGCT 2024 sull'Avanzamento delle Terapie Geniche e Cellulari per il Cancro. La presentazione si concentra su come PH-894 migliori la funzionalità e la citotossicità delle cellule Natural Killer (NK) nella lotta contro il cancro:
1. PH-894 porta a un potente e specifico silenziamento di BRD4 nelle cellule NK senza influenzare la vitalità cellulare.
2. Aumenta il numero di cellule NK potenziando la proliferazione durante l'espansione ex vivo.
3. PH-894 riduce l'espressione di CD94, un recettore inibitorio, migliorando potenzialmente il potenziale citotossico.
4. Potrebbe migliorare l'efficacia delle cellule NK nelle terapie con cellule adottive.
5. PH-894 rappresenta una base per future immunoterapie basate su cellule NK.
La presentazione di Melissa Maxwell è programmata per il 16 ottobre 2024, dalle 8:00 alle 18:45 ET nella Ballroom FDR.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) presentará datos sobre su compuesto INTASYL PH-894 en la conferencia ASGCT 2024 sobre el Avance de Terapias Genéticas y Celulares para el Cáncer. La presentación se centra en cómo PH-894 mejora la funcionalidad y la citotoxicidad de las células Natural Killer (NK) en la lucha contra el cáncer:
1. PH-894 conduce a un silenciamiento potente y específico de BRD4 en las células NK sin afectar la viabilidad celular.
2. Aumenta el número de células NK al potenciar la proliferación durante la expansión ex vivo.
3. PH-894 disminuye la expresión de CD94, un receptor inhibitorio, mejorando potencialmente el potencial citotóxico.
4. Podría mejorar la eficacia de las células NK en terapias con células adoptivas.
5. PH-894 sirve como base para futuras inmunoterapias basadas en células NK.
La presentación de Melissa Maxwell está programada para el 16 de octubre de 2024, de 8:00 a.m. a 6:45 p.m. ET en el Salón FDR.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO)는 ASGCT 2024 암 유전자 및 세포 치료 진전 회의에서 INTASYL 화합물 PH-894에 대한 데이터를 발표할 예정입니다. 발표는 PH-894가 암과 싸우는 데 있어 자연 살해(NK) 세포의 기능성과 세포 독성을 향상시키는 방법에 중점을 둡니다:
1. PH-894는 NK 세포에서 BRD4를 강력하고 특정하게 침묵시키며 세포 생존성에는 영향을 미치지 않습니다.
2. 외부 증식을 통해 NK 세포 수를 증가시킵니다.
3. PH-894는 억제 수용체인 CD94의 발현을 감소시켜 잠재적으로 세포 독성 잠재력을 향상시킵니다.
4. 채택된 세포 치료에서 NK 세포의 효능을 향상시킬 수 있습니다.
5. PH-894는 향후 NK 세포 기반 면역 요법의 토대가 됩니다.
Melissa Maxwell의 발표는 2024년 10월 16일 오전 8시부터 오후 6시 45분(ET)까지 FDR 볼룸에서 예정되어 있습니다.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) présente des données sur son composé INTASYL PH-894 lors de la conférence ASGCT 2024 sur l'Avancement des Thérapies Géniques et Cellulaires pour le Cancer. La présentation se concentre sur la manière dont PH-894 améliore la fonctionnalité et la cytotoxicité des cellules Natural Killer (NK) dans la lutte contre le cancer :
1. PH-894 entraîne un silençage puissant et spécifique de BRD4 dans les cellules NK sans affecter la viabilité cellulaire.
2. Il augmente le nombre de cellules NK en favorisant la prolifération lors de l'expansion ex vivo.
3. PH-894 diminue l'expression de CD94, un récepteur inhibiteur, ce qui peut améliorer le potentiel cytotoxique.
4. Il pourrait améliorer l'efficacité des cellules NK dans les thérapies cellulaires adoptives.
5. PH-894 sert de base pour de futures immunothérapies basées sur les cellules NK.
La présentation de Melissa Maxwell est prévue pour le 16 octobre 2024, de 8 h à 18 h 45 ET dans la salle de bal FDR.
Die Phio Pharmaceuticals Corp. (NASDAQ: PHIO) präsentiert Daten zu ihrem INTASYL-Verbindung PH-894 auf der ASGCT 2024 Konferenz über den Fortschritt von Gen- und Zelltherapien gegen Krebs. Der Fokus der Präsentation liegt darauf, wie PH-894 die Funktionalität und Zytotoxizität von natürlichen Killerzellen (NK) im Kampf gegen Krebs verbessert:
1. PH-894 führt zu einer starken und spezifischen Stilllegung von BRD4 in NK-Zellen, ohne die Zellviabilität zu beeinträchtigen.
2. Es erhöht die Anzahl der NK-Zellen, indem es die Proliferation während der ex vivo-Erweiterung fördert.
3. PH-894 verringert die Expression von CD94, einem inhibitorischen Rezeptor, der das zytotoxische Potenzial verbessern kann.
4. Es könnte die Wirksamkeit von NK-Zellen in adoptiven Zelltherapien verbessern.
5. PH-894 dient als Grundlage für zukünftige auf NK-Zellen basierende Immuntherapien.
Die Präsentation von Melissa Maxwell ist für den 16. Oktober 2024, von 8:00 bis 18:45 Uhr ET im FDR Ballsaal angesetzt.
- PH-894 shows potential to enhance NK cell functionality and cytotoxicity against cancer cells
- The compound boosts NK cell proliferation, potentially yielding more effective therapeutic doses
- PH-894 decreases expression of inhibitory receptor CD94, potentially improving NK cell cytotoxic potential
- The INTASYL compound may improve efficacy of NK cell-based adoptive cell therapies
- None.
PH-894: Potent and Specific Silencing of BRD4 in NK Cells
Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it is presenting data about its INTASYL compound PH-894 at the American Society of Gene & Cell Therapy's (ASGCT's) 2024 Advancing Gene and Cell Therapies for Cancer conference. The conference will take place virtually and at the Wyndham Hotel, Philadelphia Historic District, Philadelphia, PA.
Phio's presentation will focus on how its INTASYL compound PH-894 provides a promising approach for improving the functionality and cytotoxicity of Natural Killer (NK) cells, the body's first line of defense against cancer:
- PH-894 treatment leads to potent and specific silencing of BRD4 in NK cells, without affecting cell viability.
- Incorporation of PH-894 during ex vivo NK cell expansion protocols boosts NK cell numbers by enhancing their proliferation, potentially yielding more effective therapeutic doses.
- PH-894 treatment decreases the expression of CD94, an inhibitory receptor, allowing for improved cytotoxic potential by limiting NK cell inhibition.
- PH-894 may improve NK cell efficacy in adoptive cell therapies by boosting their immune capabilities.
The INTASYL compound PH-894 serves as a foundation for future NK cell-based immunotherapies and supports further exploration of BRD4 as a target in NK cell-based immunotherapies.
Presentation Details are as follows:
| Abstract Title: | INTASYL PH-894: Targeting BRD4 to Enhance NK Cell-Based Immunotherapy |
| Presenting Author: | Melissa Maxwell |
| Date: | October 16, 2024 |
| Time: | 8 a.m. - 6:45 p.m. ET |
| Room: | FDR Ballroom |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that it does not require specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Corporate Affairs Contact:
Jennifer Phillips
Phio Pharmaceuticals Corp.
Email: jphillips@phiopharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226613
FAQ
What is Phio Pharmaceuticals presenting at the ASGCT 2024 conference?
How does PH-894 improve NK cell functionality according to Phio Pharmaceuticals (PHIO)?
When and where is Phio Pharmaceuticals (PHIO) presenting its PH-894 data?
What potential benefits does Phio Pharmaceuticals' (PHIO) PH-894 offer for cancer treatment?
